RMP
CPRX

Richards, Merrill & Peterson’s Catalyst Pharmaceutical CPRX Stock Holding History

Richards, Merrill & Peterson’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15
Closed -$313 – 504
2024
Q4 		$313 Buy
+15
New +$322 ﹤0.01% 479

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Richards, Merrill & Peterson's CPRX Position: Q1 2025 in Review

Richards, Merrill & Peterson sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 15 shares — an estimated $313 sold.

Richards, Merrill & Peterson first reported a position in CPRX in Q4 2024 and held it in 1 quarter. The position peaked at $313 in Q4 2024. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

  • Richards, Merrill & Peterson reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Richards, Merrill & Peterson sold 15 Catalyst Pharmaceutical shares in Q1 2025, an estimated $313.
  • Richards, Merrill & Peterson first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 1 quarter.
  • Richards, Merrill & Peterson's Catalyst Pharmaceutical position peaked at $313 in Q4 2024.
  • 371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q1 2025, filed 7 May 2025.